We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.17%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$512M
AUM Growth
+$116M
Cap. Flow
+$1.26M
Cap. Flow %
0.25%
Top 10 Hldgs %
44.62%
Holding
138
New
35
Increased
30
Reduced
28
Closed
26

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$31.8M
2
BIIB icon
Biogen
BIIB
+$21.2M
3
NVS icon
Novartis
NVS
+$19M
4
PFE icon
Pfizer
PFE
+$13M
5
CELG
Celgene Corp
CELG
+$8.38M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$13.8M
2
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$13M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.9M
4
MRK icon
Merck
MRK
+$9.86M
5
AKAO
Achaogen Inc
AKAO
+$6.46M

Sector Composition

Rank Sector Weight
1 Healthcare 59.43%
2 Technology 4.38%
3 Communication Services 1.99%
4 Industrials 1.8%
5 Consumer Discretionary 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
V icon
26
Visa
V
$684B
$4.71M 0.92%
52,951
+1,000
+2% +$86K
EIGR
27
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.41M 0.86%
12,843
– –
ARDX icon
28
Ardelyx
ARDX
$1.22B
$4.36M 0.85%
345,000
+193,187
+127% +$2.54M
NICE icon
29
Nice
NICE
$5.79B
$4.32M 0.84%
63,520
+25,197
+66% +$1.73M
CBIO
30
Crescent Biopharma
CBIO
$537M
$4.21M 0.82%
7,758
+300
+4% +$184K
TXMD icon
31
TherapeuticsMD
TXMD
$23.5M
$4.18M 0.82%
+11,600
New +$3.59M
KYNB
32
Kyntra Bio
KYNB
$27.2M
$4.08M 0.8%
6,628
+400
+6% +$244K
GNCA
33
DELISTED
Genocea Biosciences, Inc.
GNCA
$3.94M 0.77%
80,784
-6,250
-7% -$244K
CHTR icon
34
Charter Communications
CHTR
$17.3B
$3.92M 0.77%
11,960
-4,205
-26% -$1.34M
TVTX icon
35
Travere Therapeutics
TVTX
$5.2B
$3.86M 0.75%
209,131
+65,157
+45% +$1.27M
CLLS
36
Cellectis
CLLS
$277M
$3.83M 0.75%
+159,664
New +$3.35M
HRTX icon
37
Heron Therapeutics
HRTX
$93.9M
$3.75M 0.73%
+250,000
New +$3.46M
GOOGL icon
38
Alphabet (Google) Class A
GOOGL
$4.36T
$3.69M 0.72%
86,920
-28,040
-24% -$1.18M
FOLD
39
DELISTED
Amicus Therapeutics
FOLD
$3.56M 0.7%
500,000
-230,000
-32% -$1.45M
SAGE
40
DELISTED
Sage Therapeutics
SAGE
$3.55M 0.69%
50,000
-40,000
-44% -$2.34M
ADMS
41
DELISTED
Adamas Pharmaceuticals
ADMS
$3.42M 0.67%
195,500
-74,500
-28% -$1.27M
AVXS
42
DELISTED
AveXis, Inc. Common Stock
AVXS
$3.42M 0.67%
45,000
– –
ALDX icon
43
Aldeyra Therapeutics
ALDX
$92.9M
$3.34M 0.65%
668,500
+300,000
+81% +$1.54M
LJPC
44
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.28M 0.64%
110,000
+59,323
+117% +$1.51M
RNAC icon
45
Cartesian Therapeutics
RNAC
$229M
$3.27M 0.64%
7,618
-1,333
-15% -$561K
CSTE icon
46
Caesarstone
CSTE
$72.3M
$3.26M 0.64%
+89,974
New +$2.9M
DBVT
47
DBV Technologies
DBVT
$799M
$3.18M 0.62%
9,017
+1,111
+14% +$390K
UNP icon
48
Union Pacific
UNP
$174B
$3.04M 0.59%
28,670
-7,406
-21% -$790K
AAP icon
49
CALL
Advance Auto Parts
AAP
$3.35B
$2.84M 0.56%
+200
New +$32.1K
KITE
50
DELISTED
Kite Pharma, Inc.
KITE
$2.75M 0.54%
35,000
-15,000
-30% -$928K
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sphera Funds Management held 138 positions worth $512M, up 29% from $395M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management's Q1 2017 filing shows 35 new, 30 increased, 28 reduced and 26 closed positions. Its largest new stake was Biogen: 75,000 shares worth $20.5M. The largest sale was Alexion Pharmaceuticals, an estimated $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 61% a quarter earlier, followed by Technology and Communication Services.

  • Sphera Funds Management's largest Q1 2017 buy was Biogen: 75,000 shares worth $20.5M.
  • Sphera Funds Management added most to Shire pic in Q1 2017, an estimated $31.8M increase.
  • Sphera Funds Management's biggest Q1 2017 reduction was Teva Pharmaceuticals, cutting an estimated $11.9M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $13.8M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $512M portfolio in Q1 2017.
  • Sphera Funds Management opened 35 new positions and closed 26 in Q1 2017.
  • Sphera Funds Management's portfolio value rose 29% quarter-over-quarter to $512M.

Based on Sphera Funds Management's 13F filing for Q1 2017, filed 11 May 2017.